A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)

Trial Profile

A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Cedazuridine/decitabine (Primary) ; Cedazuridine/decitabine (Primary) ; Decitabine
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Astex Pharmaceuticals
  • Most Recent Events

    • 25 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
    • 25 Aug 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Mar 2018.
    • 25 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top